特发性肺纤维化组织脂质组学与CT肺脂肪衰减体积分析
本研究对IPF和对照肺活检标本进行非靶向脂质组学分析,并用CT定量肺脂肪衰减体积(CTPFAV)。IPF肺组织总脂质含量显著高于对照,CTPFAV中位数也显著升高,且CTPFAV与DLCO%预计值、FVC%预计值及CT纤维化特征相关,与血清血脂无关。CTPFAV可能作为IPF疾病严重度评估的潜在生物标志物。
要点
- IPF肺组织总脂质含量显著高于对照(23.16 nmol/mg vs 18.66 mol/mg,p=0.0317)。
- IPF的CTPFAV中位数高于对照(1.34% vs 0.72%,p<0.001)。
- CTPFAV与DLCO%预计值、FVC%预计值及CT纤维化特征相关,与血清血脂无关。
核心结论
- CTPFAV是可轻松量化的无创肺脂质测量指标,在本初步研究中与IPF肺功能和放射学特征相关,可能作为IPF疾病严重度评估的潜在生物标志物。
研究设计与样本
- 研究分析IPF和对照的肺活检标本,采用非靶向脂质组学方法。
- 通过胸部CT图像用3D半自动肺密度软件评估肺脂肪衰减体积(CTPFAV),以-40至-200 HU阈值范围计算并表示为总肺体积百分比。
- CTPFAV与肺功能、血清血脂及定性CT纤维化评分进行比较。
主要发现
- 组织学分析显示IPF肺组织总脂质含量显著高于对照(23.16 nmol/mg vs 18.66 mol/mg,p=0.0317)。
- IPF的CTPFAV中位数高于对照(1.34% vs 0.72%,p<0.001)。
- 在IPF患者中,CTPFAV与DLCO%预计值(R2=0.356,p<0.0001)和FVC%预计值(R2=0.407,p<0.0001)显著相关。
- CTPFAV与CT纤维化特征相关:较高CTPFAV与>10%网状影(1.6% vs 0.94%,p=0.0017)和>10%蜂窝影(1.87% vs 1.12%,p=0.0003)相关。
- CTPFAV与血清血脂无相关性。
临床怎么用
- CTPFAV可作为无创、可量化的肺脂质指标,辅助评估IPF疾病严重度。
- CTPFAV与肺功能和CT纤维化特征相关,可结合DLCO、FVC及影像学纤维化评分综合判断。
局限性
- 本研究为初步研究(pilot study),样本量有限。
- CTPFAV与血清血脂无相关性,提示其反映局部肺脂质而非全身血脂水平。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: There is increasing interest in the role of lipids in processes that modulate lung fibrosis with evidence of lipid deposition in idiopathic pulmonary fibrosis (IPF) histological specimens. The aim of this study was to identify measurable markers of pulmonary lipid that may have utility as IPF biomarkers. STUDY DESIGN AND METHODS: IPF and control lung biopsy specimens were analysed using a unbiased lipidomic approach. Pulmonary fat attenuation volume (PFAV) was assessed on chest CT images (CTPFAV ) with 3D semi-automated lung density software. Aerated lung was semi-automatically segmented and CTPFAV calculated using a Hounsfield-unit (-40 to -200HU) threshold range expressed as a percentage of total lung volume. CTPFAV was compared to pulmonary function, serum lipids and qualitative CT fibrosis scores. RESULTS: There was a significant increase in total lipid content on histological analysis of IPF lung tissue (23.16 nmol/mg) compared to controls (18.66 mol/mg, p = 0.0317). The median CTPFAV in IPF was higher than controls (1.34% vs. 0.72%, p < 0.001) and CTPFAV correlated significantly with DLCO% predicted (R2 = 0.356, p < 0.0001) and FVC% predicted (R2 = 0.407, p < 0.0001) in patients with IPF. CTPFAV correlated with CT features of fibrosis; higher CTPFAV was associated with >10% reticulation (1.6% vs. 0.94%, p = 0.0017) and >10% honeycombing (1.87% vs. 1.12%, p = 0.0003). CTPFAV showed no correlation with serum lipids. CONCLUSION: CTPFAV is an easily quantifiable non-invasive measure of pulmonary lipids. In this pilot study, CTPFAV correlates with pulmonary function and radiological features of IPF and could function as a potential biomarker for IPF disease severity assessment.
引用
- O'Callaghan M, Duignan J, Tarling EJ, et al. Analysis of tissue lipidomics and computed tomography pulmonary fat attenuation volume (CTPFAV ) in idiopathic pulmonary fibrosis. Respirology. 2023. PMID: 37642207. doi:10.1111/resp.14582
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。